The influence of treatment with somatostatin analogues on morphology, proliferative and apoptotic activity in GH-secreting pituitary adenomas

被引:17
|
作者
Cap, J
Cerman, J
Nemecek, S
Marekova, M
Hana, V
Frysak, Z
机构
[1] Charles Univ, Fac Med, Dept Internal Med 2, Hradec Kralove, Czech Republic
[2] Charles Univ, Fac Med, Dept Med Biochem, Hradec Kralove, Czech Republic
[3] Charles Univ, Fac Med, Dept Neurosurg, Hradec Kralove, Czech Republic
[4] Charles Univ, Dept Internal Med 4, Fac Med 1, Prague, Czech Republic
[5] Palacky Univ, Fac Med, Dept Internal Med 3, CR-77147 Olomouc, Czech Republic
关键词
acromegaly; pituitary adenoma; somatostatin analogues; apoptosis; proliferation; M30; Ki-67;
D O I
10.1016/S0967-5868(03)00072-9
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
With the aim to investigate histopathological changes and proliferative and apoptotic activity in GH-secreting adenomas we compared 14 cases pre-treated with somatostatin analogues before surgery with a reference group of 17 un-pretreated ones. Besides routine histology, immunocytochemical detection of all pituitary hormones, caspase-3, cytokeratin-18, and "M30 antigen", its apoptosis-specific fragment was performed. Proliferation activity of the tumour was determined by the Ki-67 antigen expression. In treated adenomas more prominent regressive changes were found accompanied by compensatory increase in perivascular fibrosis. The Ki-67 labelling index was lower in treated group (mean 2.5, median 1.6 per mille) than in untreated patients (mean 9.4, median 5.0 per mille). The difference was statistically significant (p = 0.049 using Mann-Whitney Rank Sum Test). Apoptosis was detected in only 2 of the 14 pre-treated adenomas, and it was more frequent (9/17) and more prominent in the untreated group. (C) 2003 Elsevier Science Ltd. All rights reserved.
引用
下载
收藏
页码:444 / 448
页数:5
相关论文
共 50 条
  • [41] In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas
    Gatto, Federico
    Feelders, Richard A.
    Franck, Sanne E.
    van Koetsveld, Peter M.
    Dogan, Fadime
    Kros, Johan M.
    Neggers, Sebastian J. C. M. M.
    van der Lely, Aart-Jan
    Lamberts, Steven W. J.
    Ferone, Diego
    Hofland, Leo J.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2017, 102 (06): : 2009 - 2018
  • [42] Primary Cultures from Human GH-secreting or Clinically Non-functioning Pituitary Adenomas
    Wuerths, Roberto
    Pattarozzi, Alessandra
    Barbieri, Federica
    Florio, Tullio
    BIO-PROTOCOL, 2018, 8 (07):
  • [43] SAGE analysis highlights the putative role of underexpression of ribosomal proteins in GH-secreting pituitary adenomas
    de Lima, Deison Soares
    Martins, Clarissa Silva
    de Carvalho Paixao, Beatriz Maria
    Amaral, Fernando Colbari
    Colli, Leandro Machado
    Saggioro, Fabiano P.
    Neder, Luciano
    Machado, Helio Rubens
    Dinarte dos Santos, Anemari Ramos
    Pinheiro, Daniel G.
    Moreira, Ayrton Custodio
    Silva, Wilson Araujo, Jr.
    Castro, Margaret
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2012, 167 (06) : 759 - 768
  • [44] Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre
    Abe, T
    Lüdecke, DK
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2001, 145 (02) : 137 - 145
  • [45] INSITU HYBRIDIZATION FOR DIFFERENT MESSENGER-RNA IN GH-SECRETING AND IN INACTIVE PITUITARY-ADENOMAS
    SAEGER, W
    UHLIG, H
    BAZ, E
    FEHR, S
    LUDECKE, DK
    PATHOLOGY RESEARCH AND PRACTICE, 1991, 187 (05) : 559 - 563
  • [46] Preoperative lanreotide treatment for GH-secreting pituitary adenomas:: effect on tumour volume and predictive factors of significant tumour shrinkage
    Lucas, T
    Astorga, R
    Catalá, M
    CLINICAL ENDOCRINOLOGY, 2003, 58 (04) : 471 - 481
  • [47] Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy
    Jaquet, P
    Gunz, G
    Saveanu, A
    Dufour, H
    Taylor, J
    Dong, J
    Kim, S
    Moreau, JP
    Enjalbert, A
    Culler, MD
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2005, 153 (01) : 135 - 141
  • [48] FGFR4 Polymorphism as Molecular Determinant of the Efficacy of mTOR Inhibitors In GH-Secreting Pituitary Adenomas
    Florio, Tullio
    ENDOCRINOLOGY, 2016, 157 (09) : 3400 - 3401
  • [49] The role of GRH mediated AC-cAMP system in the pathogenesis of human, pituitary GH-secreting adenomas
    Shi, YF
    Deng, JY
    Yin, JJ
    CHINESE MEDICAL JOURNAL, 1996, 109 (08) : 603 - 608
  • [50] INVITRO EFFECT OF DOPAMINE ON GROWTH-HORMONE (GH) RELEASE FROM HUMAN GH-SECRETING PITUITARY-ADENOMAS
    SPADA, A
    SARTORIO, A
    BASSETTI, M
    PEZZO, G
    GIANNATTASIO, G
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1982, 55 (04): : 734 - 740